Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

“We believe that Zyesami has demonstrated a high degree of safety and a two-fold increase in the odds of surviving the ICU. Patients treated at the nation’s top hospitals with Zyesami had a four-fold increase in odds of survival. We will work actively with the FDA to deliver the data it has requested so that we may offer those patients another chance at life, and have asked the FDA for a Type A meeting that will include the experience of physicians who have witnessed the effects of our medicine firsthand,” Jonathan Javitt, M.D., chief executive officer of NRx said in a statement.

https://www.formularywatch.com/view/fda-rejects-eua-for-covid-19-respiratory-failure-therapy